<DOC>
	<DOCNO>NCT01235403</DOCNO>
	<brief_summary>To evaluate flexible dose escalation lacosamide , maximum approve dose 400 mg/day , clinically effective low dose individual patient , improve tolerability safety lacosamide ( 200 mg 400 mg/d ) add-on treatment patient partial onset epilepsy . Explanation acronym : SELF = Safety Efficacy Lacosamide Flexibility</brief_summary>
	<brief_title>Trial Assess Optimized Dosage Lacosamide add-on Therapy Patients With Partial Onset Seizure</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Patient diagnosis partialonset epilepsy without secondary generalization Currently take 1 3 concomitant market antiepileptic drug 18 year old study entry Previous use lacosamide Hypersensitivity component lacosamide Patients partial onset seizure clearly identifiable History generalize epilepsy History status epilepticus within last 12 month Uncountable seizure due cluster within last 12 week Non epileptic event , include pseudoseizures , conversion disorder could confuse seizure History drug alcohol abuse History suicide attempt Progressive cerebral disease Concomitant treatment felbamate Prior concomitant vigabatrin use Under legal protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Epilepsy treatment .</keyword>
	<keyword>Anti-epileptic drug</keyword>
	<keyword>Seizures</keyword>
</DOC>